Skip to main content
GutCited

연구 프로세스

477 동료 심사 연구의 그림

전체 생강 아연 이눌린 커큐민 락타아제 베르베린 차전자피 비피도박테리움 롱검 비피도박테리움 락티스 비피도박테리움 비피덤 사카로마이세스 보울라디 락토바실루스 가세리 락토바실루스 플란타룸 락토바실루스 애시도필루스 부티레이트(나트륨/칼슘 부티레이트) 페퍼민트 오일 바실루스 코아굴란스 췌장효소(판크렐리파아제) 알로에 베라(내엽 젤) 알파-갈락토시다아제 소 초유 오메가-3 지방산(EPA/DHA) 비타민 A 비타민 D 프럭토올리고당(FOS) 갈락토올리고당(GOS) L-글루타민 중쇄중성지방(MCT 오일) N-아세틸시스테인(NAC)
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 6. Effects of Clostridium butyricum and 25-hydroxyvitamin D3 on metagenome of broilers’ caecal microflora. (A) gene number venn graph. (B) core_Pan gene dilution curve. (C) species relative abundance histogram display based on genus level. (D) speci
Figure 5 Chart

Metagenomic analysis of caecal microbiota in poultry receiving Clostridium butyricum and 25-hydroxyvitamin D3 supplementation, revealing shifts in microbial community structure.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 7. Effects of Clostridium butyricum and 25-hydroxyvitamin D3 on caecal microflora on genus and species levels in broilers. (A) top 12 distinguished genus based on Kruskal_Wallis analysis; (B) top 12 distinguished species based on Kruskal_Wallis anal
Figure 6 Chart

Caecal microbial composition data from poultry treated with Clostridium butyricum and 25-hydroxyvitamin D3, showing taxonomic-level changes associated with improved bone metabolism.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 8. Effects of Clostridium butyricum and 25-hydroxyvitamin D3 on KEGG metabolic pathways of caecal microflora in broilers based on metagenomics. (A) Functional level PCA analysis. (B) Functional level PCoA analysis. (C) Heatmap of KEGG pathways. (D)
Figure 7 Chart

Metagenomic analysis of caecal microbiota in poultry receiving Clostridium butyricum and 25-hydroxyvitamin D3 supplementation, revealing shifts in microbial community structure.

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through …

Figure 1
Figure 1 Diagram

Identification of butyrate metabolism-related genes shared between metabolic-associated steatotic liver disease (MASLD) and colorectal cancer, using bioinformatic screening approaches.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 2
Figure 2 Chart

Gene expression analysis of butyrate metabolism-related shared genes across MASLD and colorectal cancer datasets, highlighting differential expression patterns.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 3
Figure 3 Chart

Functional enrichment analysis of the identified butyrate metabolism-related shared genes, mapping their involvement in key metabolic and immune pathways.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 4
Figure 4 Diagram

Protein-protein interaction network of butyrate metabolism-related genes implicated in both MASLD and colorectal cancer pathogenesis.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 5
Figure 5 Chart

Immune cell infiltration analysis in MASLD and colorectal cancer tissues, correlating butyrate metabolism gene expression with immune microenvironment composition.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 6
Figure 6 Chart

Diagnostic or prognostic model performance based on butyrate metabolism-related shared genes, using receiver operating characteristic curves or similar metrics.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 7
Figure 7 Chart

Correlation analysis between butyrate metabolism gene expression and clinical parameters in MASLD and colorectal cancer patient cohorts.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 8
Figure 8 Chart

Validation analysis of the butyrate metabolism-related shared gene signatures in independent MASLD and colorectal cancer datasets.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 9
Figure 9 Chart

Drug sensitivity or molecular docking analysis targeting butyrate metabolism-related genes shared between MASLD and colorectal cancer.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 10
Figure 10 Chart

Single-cell or transcriptomic subtype analysis of butyrate metabolism-related gene expression patterns in MASLD and colorectal cancer tissues.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 11
Figure 11 Chart

Supplementary bioinformatic analysis supporting the role of butyrate metabolism as a molecular link between MASLD and colorectal cancer.

Exploring the butyrate metabolism-related shared genes in metabolic associated steatohepatitis and ulcerative …

Figure 6
Figure 6

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic …

Figure 1. Flow diagram showing the selection of subjects for this study. FDr, functional diarrhea.
Figure 7

Figure 1. Flow diagram showing the selection of subjects for this study. FDr, functional diarrhea.

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic …

Figure 2. Changes in the percentage of loose and formed stools at baseline, 4 weeks, and 8 weeks after intervention. Changes in the proportion of formed and loose stools at (a) week 0 (baseline), (b)
Figure 8

Figure 2. Changes in the percentage of loose and formed stools at baseline, 4 weeks, and 8 weeks after intervention. Changes in the proportion of formed and loose stools at …

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic …

Figure 9
Figure 9

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic …

Figure 2
Figure 2

Overweight and vitamin D deficiency are common in patients with irritable bowel …

*= combination pills. Values are given as number (percentage). Differences were calculated between the two IBS cohorts by Fisher´s exact test. P< 0.05 was considered statistically significant
Figure 3

*= combination pills. Values are given as number (percentage). Differences were calculated between the two IBS cohorts by Fisher´s exact test. P< 0.05 was considered statistically significant

Overweight and vitamin D deficiency are common in patients with irritable bowel …

Figure 4
Figure 4

Overweight and vitamin D deficiency are common in patients with irritable bowel …

Figure 5
Figure 5

Overweight and vitamin D deficiency are common in patients with irritable bowel …

Figure 6
Figure 6

Overweight and vitamin D deficiency are common in patients with irritable bowel …

Scheme 1.Flowchart 1:The coding for mucopenetrative liposomal formulation compositions (MP1-MP6).The coding for mucopenetrative liposomal formulation compositions (MP1-MP6).
Figure 2

Scheme 1.Flowchart 1:The coding for mucopenetrative liposomal formulation compositions (MP1-MP6).The coding for mucopenetrative liposomal formulation compositions (MP1-MP6).

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

20페이지 중 17페이지